Clinical utility of entecavir for chronic hepatitis B in Chinese patients

Drug Design, Development and Therapy

Volumn 8, Issue , 2013, Pages 13-24

  Wang, Jiyao ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Entecavir; Hepatitis B; Nucleos(t)ides; People's Republic of China

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; VIRUS DNA; ADENINE; PHOSPHONIC ACID DERIVATIVE;

CHINESE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MULTIDRUG RESISTANCE; PATIENT ASSESSMENT; RECURRENT DISEASE; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS IDENTIFICATION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CHINA; COST BENEFIT ANALYSIS; ECONOMICS; HEPATITIS B, CHRONIC;

ADENINE; ANTIVIRAL AGENTS; CHINA; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; LIVER TRANSPLANTATION; ORGANOPHOSPHONATES;

EID: 84890347624     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S41423     Document Type: Review

References (62)

1. Zhang C, Zhong Y, Guo L. Strategies to prevent hepatitis B virus infection in China: immunization, screening, and standard medical practices. Biosci Trends. 2013; 7: 7-12.
2. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19: 13-24. Chinese.
3. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6: 263-283.
4. Ning LH, Hao J, Liao ZL, Zhou YY, Guo H, Zhao XY. A survey on the current trends in the management of hepatitis B in China. Eur J Gastroenterol Hepatol. 2012; 24: 884-889.
5. Sun J, Hou JL. Management of chronic hepatitis B: experience from China. J Viral Hepat. 2010; 17 Suppl 1: 10-17.
6. Anonymous. IMS China Hospital Market Overview (CHPA, 2012). 2012.
7. Yang ZG, Li YF, Zhang L, Wang J. A comparative study of entecavir dispersible tablets with entecavir in chronic hepatitis B. Journal of Bethune Military Medical College. 2012; 10: 110-111.
8. Yang GY, Zhang YG, Chen K, Chen J, Zhu YJ, Wang DW. Initial treatment of entecavir dispersible tablets in chronic hepatitis B: analysis of 52 cases. Chinese Medicine Guide. 2011; 9: 371-373.
9. Lv C, Zhang MQ. Efficacy of entecavir dispersible tablets in HBeAg-positive chronic hepatitis B patients. Journal of Medical Theory and Practice. 2012; 25: 663-664.
10. Xie YM, Zhu JR, Zhou WG. Cost-effectiveness analysis of domestic and imported entecavir in chronic hepatitis B. Journal of Medical Theory and Practice. 2012; 25: 2438-2439.
11. Xu JH, Yu YY, Si CW, et al. [A randomized, double-blind, double-dummy, controlled, multicenter study of entecavir maleate versus entecavir for treatment of HBeAg-negative chronic hepatitis B: results at week 48]. Zhonghua Gan Zang Bing Za Zhi. 2012; 20: 512-516. Chinese.
12. Luo J, Li X, Wu Y, et al. Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naive chronic hepatitis B patients in real life. Int J Med Sci. 2013; 10: 427-433.
13. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011; 106: 1264-1271.
14. Chen J, Han JH, Liu C, et al. Short-term entecavir therapy of chronic severe hepatitis B. Hepatobiliary Pancreat Dis Int. 2009; 8: 261-266.
15. Huang LH, Qiu YW, Hua HY, et al. The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus. Int J Infect Dis. 2013; 17: e606-e609.
16. Madwar MA, el Tahawy M, Strickland GT. The relationship between uncomplicated schistosomiasis and hepatitis B infection. Trans R Soc Trop Med Hyg. 1989; 83: 233-236.
17. Wei L, Hu S, Hou J, et al. A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity, and health care costs of chronic hepatitis B in China. Value in Health Regional Issues. 2013; 2: 48-56.
18. Jin X, Chen YP, Yang YD, Li YM, Zheng L, Xu CQ. Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS One. 2012; 7: e34198.
19. Yao G. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China. J Antimicrob Chemother. 2007; 60: 201-205.
20. Hou J, Jia J, Wei L, et al. Entecavir versus other standard of care for up to 4 years in nucleos(t)ide-naive patients with CHB in Chinese clinical practice. Abstract presented at the Third Asian Pacific Association for Study of the Liver, June 6-10, 2013, Singapore.
21. Yao GB, Ren H, Xu DZ, et al. Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. J Viral Hepat. 2010; 17 Suppl 1: 51-58.
22. Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007; 1: 365-372.
23. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol. 2007; 13: 4264-4267.
24. Yao G, Chen C, Lu W, et al. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008; 2: 486-493.
25. Chen EQ, Zhou TY, Liu L, et al. A comparison of treatment with adefovir and entecavir for chronic hepatitis B in China: the 2-year results of a prospective study: adefovir versus entercavir for chronic hepatitis B. Hepat Mon. 2011; 11: 27-31.
26. Wang LC, Chen EQ, Cao J, et al. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int. 2011; 5: 671-676.
27. Yan J, Ren N, Cai H, et al. The comparison of 96 weeks efficacy of lamivudine plus adefovir de novo combination therapy and entecavir monotherapy for HBeAg-positive. Hepatol Int (2013) 7 (Suppl 1): S1-S754.
28. Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clin Ther. 2010; 32: 649-658.
29. Tsai MC, Chen CH, Hung CH, et al. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. May 10, 2013. [Epub ahead of print.].
30. Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010; 13: 592-600.
31. Lee KK, Wu DB, Chow PY, Lee VW, Li H. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. J Gastroenterol Hepatol. 2012; 27: 1167-1174.
32. Lau DT, Khokhar MF, Doo E, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology. 2000; 32: 828-834.
33. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother. 2001; 12 Suppl 1: 67-71.
34. Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001; 107: 449-455.
35. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol. 2001; 21: 243-253.
36. Liu Y, Wang C, Zhong Y, et al. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat. 2011; 18: e29-e39.
37. Yao G, Zhou X, Xu D, et al. Entecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in China. Hepatol Int. 2007; 1: 373-381.
38. Zhao P, Wang C, Huang L, Xu D, Li T. Comparison of rescue strategies in lamivudine-resistant patients with chronic hepatitis B. Antiviral Res. 2012; 96: 100-104.
39. Ha M, Zhang G, Diao S, et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy. Intern Med. 2012; 51: 1509-1515.
40. Lu JJ, Liu K, Ma YJ, Wang J, Chen E-Q, Tang H. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat. 2013; 20 Suppl 1: 40-45.
41. Wang JC, He LL, Chen Q. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir. Eur Rev Med Pharmacol Sci. 2013; 17: 1162-1166.
42. Xu XH, Li GL, Qin Y, et al. Entecavir plus adefovir rescue therapy for chronic hepatitis B patients after multiple treatment failures in real-life practice. Virol J. 2013; 10: 162.
43. Xing J, Han T, Liu L, et al. [Entecavir 1. 0 mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19: 828-832. Chinese.
44. Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. February 6, 2013. [Epub ahead of print.].
45. Yang SC, Lee CM, Hu TH, et al. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother. 2013; 68: 2154-2163.
46. Wang CC, Tseng KC, Peng CY, et al. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol. 2013; 28: 46-50.
47. Basu PP, Brown RS Jr. Entecavir for the treatment of chronic hepatitis B: A clinical update for the treatment of patients with decompensated cirrhosis. Open J Intern Med. 2012; 2: 53-61.
48. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology. 2011; 54: 91-100.
49. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011; 53: 62-72.
50. Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004; 39: 857-861.
51. Xie F, Yan L, Lu J, et al. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One. 2013; 8: e54773.
52. Cui YL, Yan F, Wang YB, et al. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010; 55: 2373-2380.
53. Yan Y, Mai L, Zheng YB, et al. What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients? World J Gastroenterol. 2012; 18: 4604-4609.
54. Xie SB, Zhu JY, Ying Z, Zeng LJ, Chao M, Lu MQ. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation. 2010; 90: 786-790.
55. Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant. 2012; 26: 208-215.
56. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011; 141: 1212-1219.
57. Fung J, Chan SC, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013; 108: 942-948.
58. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int. June 14, 2011. [Epub ahead of print.].
59. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol. 1990; 8: 261-270.
60. Li HR, Huang JJ, Guo HQ, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011; 18: 877-883.
61. Chen X, Cao Z, Liu Y, et al. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with alpha-interferon plus a nucleos(t)ide analog. J Gastroenterol Hepatol. 2012; 27: 481-486.
62. Xu DZ, Wang XY, Shen XL, et al. Results of a Phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. 2013; 9: 450-456.